Percutaneous hepatic melphalan perfusion: single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: PLOS ONE, 16, 7, S. e0254817-
- Event
-
Veröffentlichung
- (where)
-
Augsburg
- (who)
-
Universität Augsburg
- (when)
-
2021
- Event
-
Veröffentlichung
- (who)
-
Public Library of Science (PLoS)
- (when)
-
2021
- Creator
-
Struck, Manuel Florian
Kliem, Peter
Ebel, Sebastian
Bauer, Alice
Gössmann, Holger
Veelken, Rhea
van Bömmel, Florian
Dennecke, Timm
Stehr, Sebastian N.
Girrbach, Felix
- DOI
-
10.1371/journal.pone.0254817
- URN
-
urn:nbn:de:bvb:384-opus4-1008662
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Struck, Manuel Florian
- Kliem, Peter
- Ebel, Sebastian
- Bauer, Alice
- Gössmann, Holger
- Veelken, Rhea
- van Bömmel, Florian
- Dennecke, Timm
- Stehr, Sebastian N.
- Girrbach, Felix
- Universität Augsburg
- Public Library of Science (PLoS)
Time of origin
- 2021
Other Objects (12)
Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers
ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma
Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience
Evaluation of Delcath Systems’ Generation 2 (GEN 2) Melphalan Hemofiltration System in a Porcine Model of Percutaneous Hepatic Perfusion
Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review
EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging
Chemosaturation with Percutaneous Hepatic Perfusions of Melphalan for Hepatic Metastases: Experience from Two European Centers
Erratum to: Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR
Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers
ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma
Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience
Evaluation of Delcath Systems’ Generation 2 (GEN 2) Melphalan Hemofiltration System in a Porcine Model of Percutaneous Hepatic Perfusion
Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review
EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging
Chemosaturation with Percutaneous Hepatic Perfusions of Melphalan for Hepatic Metastases: Experience from Two European Centers
Erratum to: Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR
Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers
ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma
Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience
Evaluation of Delcath Systems’ Generation 2 (GEN 2) Melphalan Hemofiltration System in a Porcine Model of Percutaneous Hepatic Perfusion
Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review
EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging
Chemosaturation with Percutaneous Hepatic Perfusions of Melphalan for Hepatic Metastases: Experience from Two European Centers
Erratum to: Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan